Alzheimer’s Disease (AD) comprises the accumulation of brain depositions of the beta amyloid (βA). The βA is the amyloid precursor protein (APP) digestion product, released from the cell after secretases proteolysis.This is the basis of the APP Processing Assay offered by Innoprot.
Innoprot has developed a novel fluorescence-based assay for screening of 
inhibitors of the APP Processing pathway. This novel assay requires the use of a MDCK cell line stably expressing green fluorescent APP. Treating this cell line with Aβ peptide formation inhibitors such as secretase activity inhibitors, APP appears retained in fluorescent spots. It occurs in a dose-response manner, allowing the quantification with imaging systems.
Assay: Alzheimer, Alzheimer's Disease, CNS, Modelos de enfermedad, Área terapéutica
Area: Alzheimer's Disease, CNS